Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
, 41 (17), 2682-9

Multi-centre Pilot Study of 2-chlorodeoxyadenosine and Cytosine Arabinoside Combined Chemotherapy in Refractory Langerhans Cell Histiocytosis With Haematological Dysfunction

Affiliations
Multicenter Study

Multi-centre Pilot Study of 2-chlorodeoxyadenosine and Cytosine Arabinoside Combined Chemotherapy in Refractory Langerhans Cell Histiocytosis With Haematological Dysfunction

F Bernard et al. Eur J Cancer.

Abstract

The aim of this study was to assess the efficacy and adverse effects of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (Ara-C) in children with refractory Langerhans cell histiocytosis (LCH) and haematopoietic dysfunction. Ten patients, with a median age at diagnosis of 0.5 years, were enrolled in this study. Treatment comprised at least two courses of Ara-C (1000 mg/m(2)/d) and 2-CdA (9 mg/m(2)/d) administered for 5d every 4 weeks; subsequent median follow-up was 2.8 years (range 0.03-6.4 years). Among the 7 patients who received at least two courses of therapy, disease activity decreased in 6 patients, and control of disease was achieved in all patients after a median delay of 5.5 months. All patients suffered World Health Organisation (WHO) grade 4 haematological toxicity. Two septic deaths occurred shortly after administration of the first course of 2-CdA/Ara-C; a third patient was withdrawn from the trial after the first course and subsequently died following haematopoietic stem cell transplantation. This series is small, but we conclude that 2-CdA and Ara-C combined chemotherapy probably has major activity in childhood refractory Langerhans cell histiocytosis.

Similar articles

See all similar articles

Cited by 19 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback